Granulocyte-macrophage colony-stimulating factor (GM-CSF), a hematopoietic growth factor, is currently used in patients with neutropenia induced by myelosuppression in chemotherapy to counteract the immunosuppression of sepsis (Mathias et al., 2015; Venet and Monneret, 2017). The gene discussed is CSF2; the disease is Decreased total neutrophil count.